Results of GISSi Prevenzione: diet, drugs, and cardiovascular risk. Researchers of GISSi Prevenzione
Marchioli, R.
Cardiologia 44 Suppl 1(Part 2): 745-746
1999
ISSN/ISBN: 0393-1978 PMID: 12503535 Document Number: 502933
Document emailed within 1 workday
Related Documents
Novo, S.; Mansueto, P.; Caruso, R.; Tantillo, R.; Evola, G.; Evola, S.; Strano, A.; Mansueto, S. 1999: From large trials and the GISSI Prevenzione study to field secondary prevention Cardiologia 44 Suppl. 1(Pt 2): 747-750Mafrici, A.; Mauri, F.; Maggioni, A.P.; Franzosi, M.G.; Santoro, L.; De Vita, C. 1995: Atenolol I.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. the GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico Giornale Italiano di Cardiologia 25(3): 353-364
1988: GISSI 2: Subproject on epidemiologic and genetic aspects of risk factors for myocardial infarction Giornale Italiano di Cardiologia 18(9): 770-772
Tognoni, G. 1995: Lisinopril: myocardial infarction, the first 24 hours, in patients with stable hemodynamic status. the GISSI-3 study; results at 6 weeks Archives des Maladies du Coeur et des Vaisseaux 88(Special Issue 3): 25-34
Paci, E.; Bisanti, L.; Faggiano, F. 2015: Epidemiologia e Prevenzione, a tool for the Italian Public HealthManifesto for a tobacco endgame strategy in Italy Epidemiologia e Prevenzione 39(1): 10
Gulba, D.C.; Lichtlen, P.R. 1991: Rt-PA versus streptokinase--Has the controversy regarding the optimal thrombolytic agent been resolved by results of the GISSI II/International rt-PA vs. Streptokinase fatality Study? Zeitschrift für Kardiologie 80(1): 1-5
Tognoni, G.; Franzosi, M.G. 2005: Experimenting in Italy: from GISSi to the Ministerial Decree Recenti Progressi in Medicina 96(2): 92-94
Imazio, M.; Bobbio, M.; Bergerone, S.; Barlera, S.; Maggioni, A.P. 1998: Clinical and epidemiological characteristics of juvenile myocardial infarction in Italy: the GISSi experience Giornale Italiano di Cardiologia 28(5): 505-512
Verheugt, F.W. 1990: GISSi 2; the beginning of the end or the end of the beginning for tissue plasminogen activator in acute myocardial infarct? Nederlands Tijdschrift Voor Geneeskunde 134(35): 1711-1712
Giani, P.; Avanzini, F.; Bagliani, G.; Galati, A.; Pucci, P.; Santoro, E. 1995: The predictive value for major arrhythmic events of ventricular arrhythmias, particularly nonsustained ventricular tachycardias, in the subacute phase of a fibrinolyzed infarct. An analysis of GISSI-2 data. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico Giornale Italiano di Cardiologia 25(1): 77-87
Panicker, G.K.; Karnad, D.R.; Salvi, V.; Kothari, S. 2012: Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs Journal of the Association of Physicians of India 60: 56-61
Palmieri, L.; Trojani, M.; Vanuzzo, D.; Panico, S.; Pilotto, L.; Dima, F.; Noce, C.L.; Uguccioni, M.; Pede, S.; Giampaoli, S. 2005: Distribution of the global cardiovascular risk in the Italian population: results from the cardiovascular epidemiologic observatory Italian Heart Journal. Suppl: Official Journal of the Italian Federation of Cardiology 6(5): 279-284
Bergman Marković, B.; Katić, M.; Vrdoljak, D.; Kranjcević, K.; Jasna, V.; Ivezić Lalić, D. 2010: Diet as a cardiovascular risk factor in family medicine Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 64(2): 115-122
Alušík, Štefan.; Paluch, Zoltán. 2018: Cardiovascular risk of non-steroidal anti-inflammatory drugs Vnitrni Lekarstvi 64(3): 266-271
Biamino, G.; Fenner, H.; Schüren, K.P.; Neye, J.; Ramdohr, B.; Lohmann, R.W. 1975: Cardiovascular side effects of tricyclic antidepressants - a risk in the use of these drugs International Journal of Clinical Pharmacology and Biopharmacy 11(3): 253-261
Richardson, M. 1992: Researchers seek new class of AIDS drugs Texas Medicine 88(6): 30
Kleber, M.E.; Winkler, K.; Wolfert, R.L.; Delgado, G. de Moissl; Grammer, T.B.; Dietz, S.; Winkelmann, B.R.; Boehm, B.O.; Winfried März 2011: Lipoprotein Associated Phospholipase A2 Concentration Predicts Total and Cardiovascular Mortality Independently of Established Risk Factors (The Ludwigshafen Risk and Cardiovascular Health Study) Clinical Laboratory 57(9-10): 659-667
Baena Díez, Jé.Miguel.; Del Val García, Jé.Luis.; Alemany Vilches, L.; Martínez Martínez, Jé.Luis.; Tomàs Pelegrina, J.; González Tejón, Ián.; Raidó Quintana, E.María.; Rovira España, Mónica. 2005: Risk of Suffering from Cardiovascular Diseases because of the Clustering of the Modifiable Cardiovascular Risk Factors in the Population Older than 15 years of a Health Care Center in Barcelona Revista espanola de salud publica 79: 365-378
Bueno, H.éc. 2015: Cardiovascular research continuity: a call for greater collaboration between cardiology and emergency care researchers Emergencias: Revista de la Sociedad Espanola de Medicina de Emergencias 27(6): 396-398
Laaser, U.; Schütt, A.; Kuschinsky; Gisela; Perbix, W.; Meurer, K.A.; Kaufmann, W. 1976: Cardiovascular risk factors in adolescents. 1st results of the Cologne-study 1975/76 Verhandlungen der Deutschen Gesellschaft für Innere Medizin 82 Pt 2: 1148-1151